Risedronate improves bone mineral density in Crohn's disease: A two year randomized controlled clinical trial

Journal of Crohn's and Colitis

Volumn 6, Issue 7, 2012, Pages 777-786

  Soo, Isaac ^a   Siffledeen, Jesse ^a   Siminoski, Kerry ^a   McQueen, Bob ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bisphosphonate; Crohn's disease; Osteopenia; Osteoporosis; Risedronate

Indexed keywords

CALCIUM; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTHRALGIA; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HEADACHE; HIP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SPINE; TREATMENT DURATION; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCIUM; CALCIUM CARBONATE; CROHN DISEASE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; FEMUR NECK; HIP; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; SPINE; STATISTICS, NONPARAMETRIC; VITAMIN D; YOUNG ADULT;

EID: 84862164648     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.01.004     Document Type: Article

References (34)

1. Jahnsen J., Falch J.A., Mowinckel P., Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004, 39:145-153.
2. Frei P., Fried M., Hungerbuhler V., Rammert C., Rousson V., Kullak-Ublick G.A. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion 2006, 73:40-46.
3. Habtezion A., Silverberg M.S., Parkes R., Mikolainis S., Steinhart A.H. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002, 8:87-92.
4. Siffledeen J.S., Fedorak R.N., Siminoski K., Jen H., Vaudan E., Abraham N., et al. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 2004, 10:220-228.
5. Bartram S.A., Peaston R.T., Rawlings D.J., Walshaw D., Francis R.M., Thompson N.P. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J Gastroenterol 2006, 12:5680-5686.
6. Leslie W.D., Miller N., Rogala L., Bernstein C.N. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol 2008, 103:1451-1459.
7. Silvennoinen J.A., Lehtola J.K., Niemela S.E. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996, 31:367-371.
8. van Staa T.-P., Cooper C., Brusse L.S., Leufkens H., Javaid M.K., Arden N.K. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003, 125:1591-1597.
9. Sakellariou G.T., Moschos J., Berberidis C., Mpoumponaris A., Kadis S., Molyvas E., et al. Bone density in young males with recently diagnosed inflammatory bowel disease. Joint Bone Spine 2006, 73:725-728.
10. Turk N., Cukovic-Cavka S., Korsic M., Turk Z., Vucelic B. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2009, 21:159-166.
11. Todhunter C.E., Sutherland-Craggs A., Bartram S.A., Donaldson P.T., Daly A.K., Francis R.M., et al. Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. Gut 2005, 54:1579-1584.
12. Robinson R.J., Iqbal S.J., Abrams K., Al-Azzawi F., Mayberry J.F. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998, 12:699-705.
13. Vestergaard P., Krogh K., Rejnmark L., Laurberg S., Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000, 46:176-181.
14. Klaus J., Armbrecht G., Steinkamp M., Bruckel J., Rieber A., Adler G., et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002, 51:654-658.
15. Sbrocchi A.M., Forget S., Laforte D., Azouz E.M., Rodd C. Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatr Int 2010, 52:754-761.
16. Abitbol V., Briot K., Roux C., Roy C., Seksik P., Charachon A., et al. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:1184-1189.
17. Stokkers P.C.F., Deley M., Van Der Spek M., Verberne H.J., Van Deventer S.J.H., Hommes D.W. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Scand J Gastroenterol 2006, 41:200-204.
18. Bartram S.A., Peaston R.T., Rawlings D.J., Francis R.M., Thompson N.P. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003, 18:1121-1127.
19. von Tirpitz C., Klaus J., Steinkamp M., Hofbauer L.C., Kratzer W., Mason R., et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003, 17:807-816.
20. Klaus J., Haenle M.M., Schroter C., Adler G., von Boyen G., Reinshagen M., et al. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial. Am J Gastroenterol 2011, 106:786-793.
21. Siffledeen J.S., Fedorak R.N., Siminoski K., Jen H., Vaudan E., Abraham N., et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3:122-132.
22. Haderslev K.V., Tjellesen L., Sorensen H.A., Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000, 119:639-646.
23. Tsujikawa T., Andoh A., Inatomi O., Bamba S., Nakahara T., Sasaki M., et al. Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease. Intern Med 2009, 48:933-937.
24. Cohen S., Levy R.M., Keller M., Boling E., Emkey R.D., Greenwald M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309-2318.
25. Harris S.T., Watts N.B., Li Z., Chines A.A., Hanley D.A., Brown J.P. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004, 20:757-764.
26. Boonen S., Orwoll E.S., Wenderoth D., Stoner K.J., Eusebio R., Delmas P.D. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009, 24:719-725.
27. Henderson S., Hoffman N., Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:119-123.
28. Palomba S., Orio F., Manguso F., Falbo A., Russo T., Tolino A., et al. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 2005, 16:1141-1149.
29. Palomba S., Manguso F., Orio F., Russo T., Oppedisano R., Sacchinelli A., et al. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause 2008, 15:730-736.
30. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382-387.
31. Cremers S., Sparidans R., den H.J., Hamdy N., Vermeij P., Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002, 57:883-890.
32. Bernstein C.N., Blanchard J.F., Leslie W., Wajda A., Yu B.N. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000, 133:795-799.
33. Siffledeen J.S., Siminoski K., Jen H., Fedorak R.N. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007, 5:721-728.
34. Pazianas M., Abrahamsen B. Safety of bisphosphonates. Bone 2011, 49:103-110.